X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (233) 233
hematology (155) 155
middle aged (149) 149
adult (147) 147
male (129) 129
female (128) 128
aged (127) 127
oncology (106) 106
prognosis (76) 76
index medicus (74) 74
aged, 80 and over (54) 54
adolescent (53) 53
antineoplastic combined chemotherapy protocols - therapeutic use (53) 53
treatment outcome (49) 49
article (44) 44
antineoplastic agents - therapeutic use (39) 39
remission induction (39) 39
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (37) 37
therapy (35) 35
leukemia (33) 33
chronic myelogenous leukemia (32) 32
leukemia, myeloid, acute - drug therapy (28) 28
research (28) 28
young adult (27) 27
acute myeloid-leukemia (26) 26
cancer (26) 26
recurrence (25) 25
antineoplastic combined chemotherapy protocols - adverse effects (24) 24
chronic myeloid-leukemia (24) 24
survival rate (24) 24
chemotherapy (23) 23
cytarabine - administration & dosage (23) 23
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (23) 23
survival analysis (23) 23
hemic and lymphatic diseases (22) 22
combined modality therapy (21) 21
follow-up studies (21) 21
philadelphia chromosome (21) 21
health aspects (20) 20
acute disease (18) 18
bone marrow - pathology (18) 18
care and treatment (18) 18
imatinib mesylate (18) 18
karyotyping (18) 18
leukemia, myelogenous, chronic, bcr-abl positive - genetics (18) 18
retrospective studies (18) 18
risk factors (18) 18
acute lymphoblastic-leukemia (17) 17
benzamides (17) 17
chronic myeloid leukemia (17) 17
disease-free survival (17) 17
drug therapy (17) 17
myelodysplastic syndrome (17) 17
pyrimidines - therapeutic use (17) 17
salvage therapy (17) 17
acute myeloid leukemia (16) 16
antineoplastic agents - adverse effects (16) 16
bone marrow transplantation (16) 16
chromosome aberrations (16) 16
drug resistance, neoplasm (16) 16
leukemia, myelogenous, chronic, bcr-abl positive - pathology (16) 16
leukemia, myelogenous, chronic, bcr-abl positive - therapy (16) 16
mutation (16) 16
survival (16) 16
vincristine - administration & dosage (16) 16
acute myelogenous leukemia (15) 15
cells (15) 15
drug administration schedule (15) 15
leukemia, myeloid, acute - genetics (15) 15
myelodysplastic syndromes (15) 15
piperazines - therapeutic use (15) 15
cyclophosphamide - administration & dosage (14) 14
interferon-alpha - therapeutic use (14) 14
leukemia, myeloid - drug therapy (14) 14
age factors (13) 13
bcr-abl (13) 13
classification (13) 13
cml (13) 13
imatinib (13) 13
nilotinib (13) 13
protein kinase inhibitors - therapeutic use (13) 13
protein-tyrosine kinases - antagonists & inhibitors (13) 13
relapse (13) 13
analysis (12) 12
clinical trials as topic (12) 12
doxorubicin - administration & dosage (12) 12
genetic aspects (12) 12
leukocyte count (12) 12
transplantation (12) 12
antineoplastic combined chemotherapy protocols - administration & dosage (11) 11
bone-marrow transplantation (11) 11
chronic lymphocytic-leukemia (11) 11
cytarabine - therapeutic use (11) 11
diagnosis (11) 11
fusion proteins, bcr-abl - genetics (11) 11
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (11) 11
neoplasms (11) 11
platelet count (11) 11
precursor cell lymphoblastic leukemia-lymphoma - mortality (11) 11
animals (10) 10
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
2008, Hematologic malignancies, ISBN 3540723021, x, 294
Better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells. Thus, several... 
Acute leukemia -- Treatment | Acute leukemia | Clinical & internal medicine
Book
Leukemia Research, ISSN 0145-2126, 2007, Volume 31, pp. S112 - S112
Journal Article
Leukemia Research, ISSN 0145-2126, 2007, Volume 31, pp. S38 - S39
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 25, pp. 2386 - 2398
Among patients with IDH1 -mutated relapsed or refractory leukemia, daily oral ivosidenib, an IDH1 inhibitor, induced molecular clearance of leukemic cells from... 
MEDICINE, GENERAL & INTERNAL | IDH2 MUTATIONS | METAANALYSIS | ACUTE MYELOID-LEUKEMIA | PROGNOSTIC-SIGNIFICANCE | DIFFERENTIATION | INHIBITOR | Glycine - analogs & derivatives | Recurrence | Follow-Up Studies | Glycine - adverse effects | Cell Count | Humans | Middle Aged | Pyridines - pharmacokinetics | Drug Resistance, Neoplasm | Male | Isocitrate Dehydrogenase - antagonists & inhibitors | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Young Adult | Pyridines - adverse effects | Enzyme Inhibitors - pharmacokinetics | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Glycine - administration & dosage | Enzyme Inhibitors - adverse effects | Glycine - pharmacokinetics | Pyridines - administration & dosage | Administration, Oral | Isocitrate Dehydrogenase - genetics | Survival Rate | Remission Induction | Leukemia, Myeloid, Acute - mortality | Adolescent | Aged | Mutation | Hemoglobins - analysis | Leukemia, Myeloid, Acute - genetics | Usage | Myelocytic leukemia | Gene mutations | Physiological aspects | Genetic aspects | Nonlymphoid leukemia | Research | Drug therapy | Isocitrate dehydrogenase | Risk factors | Thrombocytopenia | Myeloid leukemia | Leukemia | FDA approval | Cancer therapies | Patients | Investigations | Leukocytosis | Collaboration | Point mutation | Remission | Acute myeloid leukemia | Drug dosages | Neutropenia | Tumors
Journal Article
American Journal of Hematology, ISSN 0361-8609, 05/2013, Volume 88, Issue 5, pp. 350 - 354
Omacetaxine mepesuccinate (omacetaxine) is a first‐in‐class cephalotaxine with a unique mode of action, independent of BCR‐ABL, that has shown promising... 
CHRONIC MYELOGENOUS LEUKEMIA | CELLS | APOPTOSIS | THERAPY | BCR-ABL | IMATINIB | DOWN-REGULATION | HOMOHARRINGTONINE | HEMATOLOGY | FAILURE | NILOTINIB | Drug Resistance, Multiple | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Harringtonines - adverse effects | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Harringtonines - therapeutic use | Protein Synthesis Inhibitors - administration & dosage | Hematopoiesis - drug effects | Maintenance Chemotherapy - adverse effects | Young Adult | Antineoplastic Agents, Phytogenic - administration & dosage | Antineoplastic Agents - adverse effects | Injections, Subcutaneous | Harringtonines - administration & dosage | Adult | Bone Marrow Cells - drug effects | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Antineoplastic Agents, Phytogenic - adverse effects | Leukemia, Myeloid, Chronic-Phase - blood | Leukemia, Myeloid, Chronic-Phase - drug therapy | Bone Marrow Cells - pathology | Induction Chemotherapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Survival Analysis | Aged | Drug Monitoring | Protein Synthesis Inhibitors - adverse effects | Protein Synthesis Inhibitors - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Phenols | Research | Chronic myeloid leukemia | Oncology, Experimental | Cancer | Index Medicus
Journal Article
Leukemia, ISSN 0887-6924, 2012, Volume 26, Issue 9, pp. 2061 - 2068
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 612 - 621
Journal Article
Journal Article
Journal Article
Leukemia, ISSN 0887-6924, 06/2008, Volume 22, Issue 6, pp. 1200 - 1206
Journal Article